@article{Mullish:2018:10.1016/j.jhin.2018.07.037,
author = {Mullish, BH and Quraishi, MN and Segal, JP and McCune, VL and Baxter, M and Marsden, GL and Moore, D and Colville, A and Bhala, N and Iqbal, TH and Settle, C and Kontkowski, G and Hart, AL and Hawkey, PM and Williams, HRT and Goldenberg, SD},
doi = {10.1016/j.jhin.2018.07.037},
journal = {Journal of Hospital Infection},
pages = {S1--S31},
title = {The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines},
url = {http://dx.doi.org/10.1016/j.jhin.2018.07.037},
volume = {100},
year = {2018}
}

Download

TY  - JOUR
AB  - Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the United Kingdom (UK) have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.
AU  - Mullish,BH
AU  - Quraishi,MN
AU  - Segal,JP
AU  - McCune,VL
AU  - Baxter,M
AU  - Marsden,GL
AU  - Moore,D
AU  - Colville,A
AU  - Bhala,N
AU  - Iqbal,TH
AU  - Settle,C
AU  - Kontkowski,G
AU  - Hart,AL
AU  - Hawkey,PM
AU  - Williams,HRT
AU  - Goldenberg,SD
DO  - 10.1016/j.jhin.2018.07.037
EP  - 31
PY  - 2018///
SN  - 0195-6701
SP  - 1
TI  - The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
T2  - Journal of Hospital Infection
UR  - http://dx.doi.org/10.1016/j.jhin.2018.07.037
UR  - http://hdl.handle.net/10044/1/62909
VL  - 100
ER  - 

Download